E-Health: Web-guided therapy and disease self-management in ulcerative colitis: Impact on disease outcome, quality of life and compliance

Danish Medical Journal

Volumn 59, Issue 7, 2012, Pages

  Elkjaer, Margarita ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BALSALAZIDE; BUDESONIDE; CALGRANULIN; HYDROCORTISONE ACETATE; MESALAZINE; OLSALAZINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; HEALTH CARE QUALITY; HOSPITALIZATION; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; QUALITY OF LIFE; RAPID TEST; SELF CARE; ULCERATIVE COLITIS; ADOLESCENT; ATTITUDE TO HEALTH; CHEMISTRY; FECES; INTERNET; METHODOLOGY; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT EDUCATION; PSYCHOLOGICAL ASPECT; QUALITY CONTROL; REVIEW; SEVERITY OF ILLNESS INDEX;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENCHMARKING; COLITIS, ULCERATIVE; FECES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERNET; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MEDICATION ADHERENCE; MESALAMINE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; QUALITY OF LIFE; SELF CARE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84873266479     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996 Nov;39(5):690-7.
2. Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006 Jun;101(6):1274-82.
3. Jacobsen BA, Fallingborg J, Rasmussen HH, Nielsen KR, Drewes AM, Puho E, et al. Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978-2002. Eur J Gastroenterol Hepatol 2006 Jun;18(6):601-6.
4. World Health Organization, http://www.who.int/en/. 2007. Ref Type: Internet Communication
5. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008 Feb;134(2):577-94.
6. Vermeire S, Rutgeerts P. Current status of genetics research in inflammatory bowel disease. Genes Immun 2005 Dec;6(8):637-45.
7. Vind I, Riis L, Jespersgaard C, Jess T, Knudsen E, Pedersen N, et al. Genetic and environmental factors as predictors of disease severity and extent at time of diagnosis in an inception cohort of inflammatory bowel disease, Copenhagen County and City 2003-2005. J Crohns Colitis 2008 Jun;2(2):162-9.
8. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994 Jul;107(1):3-11.
9. Munkholm P. Crohn's disease--occurrence, course and prognosis. An epidemiologic cohort-study. Dan Med Bull 1997 Jun;44(3):287-302.
10. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004 Feb;126(2):402-13.
11. D'Haens GR. Top-down therapy for Crohn's disease: rationale and evidence. Acta Clin Belg 2009 Nov;64(6):540-6.
12. Langholz E, Munkholm P, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol 1991 Dec;26(12):1247-56.
13. Kane SV, Bjorkman DJ. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Disord 2003;3(4):210-8.
14. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005 Nov;100(11):2478-85.
15. Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997 Oct;92(10):1867-71.
16. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a casecontrol study. Aliment Pharmacol Ther 2000 Feb;14(2):145-53.
17. El-Serag HB. Translational research: the study of community effectiveness in digestive and liver disorders. Gastroenterology 2007 Jan;132(1):8-10.
18. Kane SV, Robinson A. Review article: understanding adherence to medication in ulcerative colitis-innovative thinking and evolving concepts. Aliment Pharmacol Ther 2010 Nov;32(9):1051-8.
19. Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest 2006 Jul;130(1 Suppl):65S-72S.
20. Shale MJ, Riley SA. Studies of compliance with delayedrelease mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003 Jul 15;18(2):191-8.
21. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001 Oct;96(10):2929-33.
22. Jackson CA, Clatworthy J, Robinson A, Horne R. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol 2010 Mar;105(3):525-39.
23. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003 Jan;114(1):39-43.
24. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 2008;53:1020-4.
25. European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry www.cocir.org. 2010. Ref Type: Internet Communication
26. Euract. com e-Health update10.03.10. 2010. Ref Type: Internet Communication
27. Commission of the European Communities, Brussels, 04.11.2008, Com (2008) 689, final Communication from the commission to the European Parliament, the council, the European economic and social committee and the committee of the regions on telemedicine for the benefit of patients, healthcare systems and society. 2010. Ref Type: Internet Communication
28. Commission of the EU Communities, Brussels, 30.04.2004, Com (2004) 356, final. 2010. Ref Type: Internet Communication
29. Commission Recommendation, Brussels, 02.07.2008, Com (2008) 3282, final. 2010. Ref Type: Internet Communication
30. Rasmussen LM, Phanareth K, Nolte H, Backer V. Internet-based monitoring of asthma: a long-term, randomized clinical study of 300 asthmatic subjects. J Allergy Clin Immunol 2005 Jun;115(6):1137-42.
31. van der Meer V, Bakker MJ, van den Hout WB, Rabe KF, Sterk PJ, Kievit J, et al. Internet-based self-management plus education compared with usual care in asthma: a randomized trial. Ann Intern Med 2009 Jul 21;151(2):110-20.
32. Meyer B, Berger T, Caspar F, Beevers CG, Andersson G, Weiss M. Effectiveness of a novel integrative online treatment for depression (Deprexis): randomized controlled trial. J Med Internet Res 2009;11(2):e15.
33. van Straten A., Cuijpers P, Smits N. Effectiveness of a web-based self-help intervention for symptoms of depression, anxiety, and stress: randomized controlled trial. J Med Internet Res 2008;10(1):e7.
34. Cox D, Ritterband L, Magee J, Clarke W, Gonder-Frederick L. Blood glucose awareness training delivered over the internet. Diabetes Care 2008 Aug;31(8):1527-8.
35. van Bastelaar KM, Pouwer F, Cuijpers P, Riper H, Snoek FJ. Web-Based Depression Treatment for Type 1 and Type 2 Diabetic Patients: A randomized, controlled trial. Diabetes Care 2011 Feb;34(2):320-5.
36. Bond GE, Burr RL, Wolf FM, Feldt K. The effects of a web-based intervention on psychosocial well-being among adults aged 60 and older with diabetes: a randomized trial. Diabetes Educ 2010 May;36(3):446-56.
37. Cho JH, Chang SA, Kwon HS, Choi YH, Ko SH, Moon SD, et al. Long-term effect of the Internet-based glucose monitoring system on HbA1c reduction and glucose stability: a 30-month follow-up study for diabetes management with a ubiquitous medical care system. Diabetes Care 2006 Dec;29(12):2625-31.
38. McMahon GT, Gomes HE, Hickson HS, Hu TM, Levine BA, Conlin PR. Web-based care management in patients with poorly controlled diabetes. Diabetes Care 2005 Jul;28(7):1624-9.
39. Evangelista LS, Stromberg A, Westlake C, Ter-Galstanyan A, Anderson N, Dracup K. Developing a Web-based education and counseling program for heart failure patients. Prog Cardiovasc Nurs 2006;21(4):196-201.
40. Kelly JJ, Sweigard KW, Shields K, Schneider D. John M. Eisenberg Patient Safety Awards. Safety, effectiveness, and efficiency: a Web-based virtual anticoagulation clinic. Jt Comm J Qual Saf 2003 Dec;29(12):646-51.
41. McManus RJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S, et al. Telemonitoring and selfmanagement in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet 2010 Jul 17;376(9736):163-72.
42. Kashem A, Droogan MT, Santamore WP, Wald JW, Marble JF, Cross RC, et al. Web-based Internet telemedicine management of patients with heart failure. Telemed J E Health 2006 Aug;12(4):439-47.
43. Postel MG, de Haan HA, ter Huurne ED, Becker ES, de Jong CA. Effectiveness of a web-based intervention for problem drinkers and reasons for dropout: randomized controlled trial. J Med Internet Res 2010;12(4):e68.
44. Hunt DL, Haynes RB, Hanna SE, Smith K. Effects of computer-based clinical decision support systems on physician performance and patient outcomes: a systematic review. JAMA 1998 Oct 21;280(15):1339-46.
45. Centre for Evidence Based Medicine, Oxford. Levels of evidence and grades of recommendation http://www.cebm.net/levelsofevidence.asp. 2007. Ref Type: Internet Communication
46. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998 Jul;43(1):29-32.
47. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol 1996 Aug;91(8):1571-8.
48. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992 Sep;27(9):793-8.
49. Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990 Sep 29;336(8718):763-5.
50. Yui S, Mikami M, Tsurumaki K, Yamazaki M. Growthinhibitory and apoptosis-inducing activities of calprotectin derived from inflammatory exudate cells on normal fibroblasts: regulation by metal ions. J Leukoc Biol 1997 Jan;61(1):50-7.
51. Fagerhol MK, Dale I, Anderson I. Release and quantitation of a leukocyte derived protein (L1). Scand J Gastroenterol 1980;24:393-8.
52. Walkiewicz D, Werlin SL, Fish D, Scanlon M, Hanaway P, Kugathasan S. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008 May;14(5):669-73.
53. Langholz E. Ulcerative colitis. An epidemiological study based on a regional inception cohort, with special reference to disease course and prognosis. Dan Med Bull 1999 Nov;46(5):400-15.
54. Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet; 1986. p. 307-10.
55. Altman D.G. Practical Statistics for Medical Research. Chapman & Hall, 1991. p. 410-1.
56. Van der Eijk I, Stockbrugger R, Russel M. Influence of quality of care on quality of life in inflammatory bowel disease (IBD): literature review and studies planned. Eur J Intern Med 2000 Aug;11(4):228-34.
57. Van der Eijk I, Vlachonikolis IG, Munkholm P, Nijman J, Bernklev T, Politi P, et al. The role of quality of care in health-related quality of life in patients with IBD. Inflamm Bowel Dis 2004 Jul;10(4):392-8.
58. Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006 Mar;55 Suppl 1:i36-i58.
59. Biancone L, Michetti P, Travis S, Escher JC, Moser G, Forbes A, et al. European evidence-based Consensus on the management of ulcerative colitis: Special situations. J Crohns Colitis 2008 Mar;2(1):63-92.
60. Waters BM, Jensen L, Fedorak RN. Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. Can J Gastroenterol 2005 Apr;19(4):235-44.
61. Politi P, Bodini P, Mortilla MG, Beltrami M, Fornaciari G, Formisano D, et al. Communication of information to patients with inflammatory bowel disease: A European Collaborative Study in a multinational prospective inception cohort. J Crohns Colitis 2008 Sep;2(3):226-32.
62. Robinson A, Thompson DG, Wilkin D, Roberts C. Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. Lancet 2001 Sep 22;358(9286):976-81.
63. Westwood N, Travis SP. Review article: what do patients with inflammatory bowel disease want for their clinical management? Aliment Pharmacol Ther 2008 Mar;27 Suppl 1:1-8.
64. Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohns Colitis 2007 Sep;1(1):10-20.
65. Reinisch W, Sandborn WJ, Bala M, Yan S, Feagan BG, Rutgeerts P, et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis 2007 Sep;13(9):1135-40.
66. Travis SPL, Stange EF, Lqmann M, Iresland T, Bemelman WA, Chowers Y, et al. Corrigendum to "Europeanevidence-based consensus on the management of ulcerative colitis: Current management" [J Crohns & Colitis 2 (2008) 24-62]. Journal of Crohn's and Colitis 2008 Jun;2(2):190.
67. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000 May;95(5):1263-76.
68. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a metaanalysis. Gut 1997 Jun;40(6):775-81.
69. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003 May;1(3):170-3.
70. Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, et al. Randomised trial of once-or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008 Jul;57(7):893-902.
71. Prantera C, Kohn A, Campieri M, Caprilli R, Cottone M, Pallone F, et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther 2009 Nov 1;30(9):908-18.
72. Loftus EV, Jr. A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies. Inflamm Bowel Dis 2006 Dec;12(12):1107-13.
73. Kane SV, Brixner D, Rubin DT, Sewitch MJ. The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm 2008 Jan;14(1 Suppl A):s2-12.
74. Higgins PD, Rubin DT, Kaulback K, Schoenfield PS, Kane SV. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther 2009 Feb 1;29(3):247-57.
75. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;(2):CD000544.
76. Kruis W, Jonaitis L, Pokrotnieks J, Mikhailova TL, Horynski M, Batovsky M, et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther 2011 Feb;33(3):313-22.
77. Christensen LA, Fallingborg J, Jacobsen BA, Abildgaard K, Rasmussen HH, Hansen SH, et al. Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation. Aliment Pharmacol Ther 1994 Jun;8(3):289-94.
78. Cross RK, Cheevers N, Finkelstein J. Home telemanagement for patients with ulcerative colitis (UC HAT). Dig Dis Sci 2009 Nov;54(11):2463-72.
79. Vestergaard TA, Nielsen SL, Dahlerup JF, Hornung N. Fecal calprotectin: assessment of a rapid test. Scand J Clin Lab Invest 2008;68(4):343-7.